342373-40-4

Basic information

• Product Name: 3-(4-bromophenyl)-N-hydroxypropanamide
• Synonyms: 3-(4-bromophenyl)-N-hydroxypropanamide
• CAS NO: 342373-40-4
• Molecular Weight: 244.088
• Mol File: 342373-40-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(4-bromophenyl)-N-hydroxypropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-bromophenyl)-N-hydroxypropanamide(342373-40-4)
• EPA Substance Registry System: 3-(4-bromophenyl)-N-hydroxypropanamide(342373-40-4)

Safety Data

• Hazardous Substances Data: 342373-40-4(Hazardous Substances Data)

Usage

Functional groups

amide and hydroxamic acid

Structure

bromine-substituted benzene ring and hydroxamic acid attached to a three-carbon chain

Uses

building block in organic synthesis, pharmaceutical research

Properties

chelating agent, inhibitory activity against certain enzymes

Applications

drug development, medicinal chemistry

Upstream product

• 1643-30-7 3-(4-bromophenyl)propionic acid 
• 55394-81-5 3-(4-bromophenyl)propanoyl chloride 

Downstream Products

• 3279-90-1 6-bromo-3,4-dihydro-1H-quinolin-2-one 

Relevant articles and documents

Visible-Light Induced C(sp2)?H Amidation with an Aryl–Alkyl σ-Bond Relocation via Redox-Neutral Radical–Polar Crossover

We report an approach for the intramolecular C(sp2)?H amidation of N-acyloxyamides under photoredox conditions to produce δ-benzolactams with an aryl-alkyl σ-bond relocation. Computational studies on the designed reductive single electron transfer strategy led us to identify N-[3,5-bis(trifluoromethyl)benzoyl] group as the most effective amidyl radical precursor. Upon the formation of an azaspirocyclic radical intermediate by the selective ipso-addition with outcompeting an ortho-attack, radical–polar crossover was then rationalized to lead to the rearomative ring-expansion with preferential C?C bond migration.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.